Intracellular Delivery Target Feldan Therapeutics as a partner for intracellular delivery capabilities through Feldan Shuttle to address diseases where conventional therapies fail, focusing on respiratory and skin conditions.

Clinical-Stage Signals Leverage Feldan's clinical-stage status and ongoing Series B financing history to discuss collaboration or co-development opportunities, highlighting near-term clinical milestones and potential co-funding.

Strategic Partnerships Position Feldan as a interest for venture and pharma collaborations, referencing recent investor activity (Zynext Ventures) and CF Foundation funding to validate market relevance and potential for strategic alliances.

Regulatory & Funding Momentum Capitalize on the regulatory-friendly trajectory of intracellular therapies and prior grant support to propose grant-backed development programs or milestone-based deals with risk-sharing.

Market Expansion Identify opportunities in respiratory and dermatology spaces where intracellular delivery can unlock new modalities, offering early-tailored pilots or discovery collaborations to expand Feldan’s addressable markets.